Protagonist Therapeutics (PTGX) Current Deferred Revenue (2017 - 2026)

Protagonist Therapeutics (PTGX) has 10 years of Current Deferred Revenue data on file, last reported at $6.3 million in Q1 2026.

• For the quarter ending Q1 2026, Current Deferred Revenue fell 62.82% year-over-year to $6.3 million; the trailing twelve-month figure through Mar 2026 stood at $6.3 million (down 62.82% YoY), and the FY2025 full-year result was $9.5 million, down 49.45% from the prior year.
• Current Deferred Revenue declined to $6.3 million in Q1 2026, from $9.5 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $45.0 million in Q1 2024 to a low of $3000.0 in Q3 2023.
• A 5-year average of $11.9 million and a median of $11.9 million in 2025 frame the typical range for Current Deferred Revenue.
• Across the five-year window, Current Deferred Revenue slumped 98.57% in 2022 and surged 656433.33% in 2024, its largest moves.
• Tracing PTGX's Current Deferred Revenue over 5 years: stood at $69000.0 in 2022, then slumped by 95.65% to $3000.0 in 2023, then surged by 629600.0% to $18.9 million in 2024, then plunged by 49.45% to $9.5 million in 2025, then plunged by 34.22% to $6.3 million in 2026.
• Business Quant data shows PTGX's Current Deferred Revenue at $6.3 million in Q1 2026, $9.5 million in Q4 2025, and $14.2 million in Q3 2025.